Azurity Pharmaceuticals Announces FDA Approval of Myhibbin™

Azurity Pharmaceuticals, a company dedicated to developing innovative dose forms and formulations to meet the needs of overlooked patients, has announced that the U.S. Food and Drug Administration (FDA) has approved Myhibbin™, a ready-to-use oral suspension of mycophenolate mofetil. This medication is an antimetabolite immunosuppressant, primarily used to prevent organ rejection following a transplant. In 2023, the United States saw over 46,000 transplants, and patients require daily medication to avoid rejection.

Myhibbin is prescribed for the prevention of organ rejection in both adult and pediatric patients, starting from three months of age, who have received allogeneic kidney, heart, or liver transplants. This treatment must be used in combination with other immunosuppressants. 

Richard Blackburn, CEO of Azurity Pharmaceuticals, expressed satisfaction with the FDA's approval, highlighting the importance of Myhibbin for organ transplant recipients. He emphasized that the primary goal is to provide new formulations that help patients benefit from existing medications. Myhibbin's ready-to-use liquid formulation offers a convenient alternative to other dosage forms of mycophenolate, benefiting patients, pharmacists, and caregivers alike.

Azurity Pharmaceuticals, Inc. is committed to offering high-quality, innovative medicines for patients whose needs are often overlooked. The company supplies a wide range of products to treat various medical conditions, including cardiovascular, central nervous system, endocrine, gastrointestinal, anti-infective, and oncology issues. Many of their products are designed as dose-form innovations, targeting patients whose needs are not addressed by other available medications. Azurity's medicines have positively impacted millions of lives.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!